VCP and plasma cell myeloma: This speculation is based on effects of bortezomib (Velcade), a proteasome inhibitor currently used for treatment of multiple myeloma and mantle-cell lymphoma and fascinating results showing that p97 inhibitor significantly reduced NSCLC tumor growth in in vitro and in vivo models (Valle et al., 2011).